Navigation Links
Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
Date:6/23/2008

NEW YORK, June 23 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Brian Levy, OD, MSc as its Chief Operating Officer.

"Dr. Levy's depth and breathe of experience in clinical operations, drug and device development and medical affairs make him an excellent addition to Danube's senior management team. I look forward to his working with us in successfully developing our drug candidates and expanding our pipeline," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.

Prior to joining Danube, since 2004, Dr. Levy served as Corporate Vice President and Chief Medical Officer of Bausch & Lomb worldwide. He was responsible for clinical development and research, global product safety and medical affairs. In this role Dr. Levy drove the development and subsequent approval of multiple ophthalmic pharmaceutical products and ophthalmic devices globally, including the only approved intra-ocular sustained release steroid drug delivery system. Dr. Levy joined Bausch & Lomb in 1994 as Director, Medical Clinical Affairs. Prior to joining Bausch & Lomb, from 1989 to 1994, Dr. Levy served as Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco. Before that he studied epidemiology and biostatistics in vision research through the National Institutes of Health and then proceeded into private clinical practice for 10 years. During this period Dr. Levy was a clinical investigator for numerous products in development and an advisor and consultant to the ophthalmic industry.

Dr. Levy currently holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester's School of Medicine. He received a Doctor of Optometry degree from the University of California at Berkeley and did his pos
'/>"/>

SOURCE Danube Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
2. MiMedx Announces Brian J. Splan as President
3. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
6. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
7. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
8. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
9. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
10. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... 2015 YourEncore, an Indianapolis, Indiana-based ... consumer products and food sciences industries solve complex ... for Clinical Research Excellence and Safety (ACRES), a ... clinical research, have partnered to speed innovation in ... YourEncore brings to ACRES experts with proven experience, ...
(Date:4/20/2015)... , April 20, 2015 Orthobiologics ... healing bone injuries. The orthobiologics market is a rewarding ... its stakeholders. The global orthobiologics market report defines and ... revenue. The global orthobiologics market was valued at $5,712.4 ... million by 2019, at a CAGR of 6.7% from ...
(Date:4/20/2015)...  "Everybody is affected by cancer sooner or later," ... brutal. We,ve got to get away from that."  If ... a loved one or friend battling for their life ... and other treatments cause the human body. It,s almost ... and succumb to the disease. Dr. Dionne has developed ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... II study of 20 patients reported in Annals ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) today ... of a limited phase II study of CHOP ... Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60,years of ...
... 4 Vermillion, Inc.,(Nasdaq: VRMLD ), a ... diagnostic test programs and provided a preview,of key ... course of 2008. The,Company also released financial results ... 2007., "In 2007, Vermillion made significant clinical ...
... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time,members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: ... the company,s recent,transactions targeting cleaning up the capital structure, and upcoming,product and sales milestones., ... Conference Call Numbers ... Wednesday, ...
Cached Biology Technology:CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... working on the fundamental biological processes of plants could ... many parts of the world. Using model plant species, ... uncovered one of the processes used by the plants ... discoveries are now being applied to improve the productivity ...
... geochemists from the University of Southern California and Rice ... that could power spy drones that fit in the ... long been interested in micro-scale air vehicles ?some as ... the lack of a suitable, compact power source. With ...
... at the Max Planck Institute of Biochemistry in Martinsried, ... that blocking blood vessel development in a tumour slows ... principle led to the development of SUTENT®, whose active ... use in the United States, and it is expected ...
Cached Biology News:Sun protection for plants 2USC, Rice to develop bacteria-powered fuel cells 2Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... The Jouan RC Sensitive Bio (for heat-labile ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: